Clinical Trials Browser

Phase 1/2 × Breast Neoplasms × patritumab deruxtecan × Clear all

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT02980341 2024-10-30

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Phase 1/2 Completed

182 enrolled 37 charts

Breast Neoplasms, Neoplasms